SITC Melanoma
Immunotherapy Guideline

SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent, and balanced. CPGs will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

SITC continuously evaluates the field for practice-changing data and new FDA approvals. An update to this CPG is in progress.

SITC Melanoma Immunotherapy Guideline Expert Panel

Members

Charlotte E. Ariyan, MD, PhD — Memorial Sloan Kettering Cancer Center

Elizabeth Buchbinder, MD — Dana-Farber Cancer

Diwaker Davar, MBBS, MSc — UPMC Hillman Cancer Center

Geoffrey T. Gibney, MD — Georgetown Lombardi Comprehensive Cancer 

Omid Hamid, MD — Cleveland Clinic Cancer Center

Tina J. Hieken, MD — Mayo Clinic

Benjamin Izar, MD, PhD — Columbia University

Douglas B. Johnson, MD, MSCI — Vanderbilt University Medical Center

Rajan Kulkarni, MD, PhD — Oregon Health & Science University

Jason J. Luke, MD, FACP — UPMC Hillman Cancer Center

Tara C. Mitchell, MD, PhD — University of Pennsylvania

Meghan J. Mooradian, MD — Massachusetts General Hospital Cancer Center

Krista M. Rubin, MS, FNP-BC — Massachusetts General Hospital

April K.S. Salama, MD — Duke University

Keisuke Shirai, MD — Dartmouth-Hitchcock Medical Center

Janis M. Taube, MD, MSc — Johns Hopkins School of Medicine

Hussein A. Tawbi, MD, PhD — The University of Texas MD Anderson Cancer Center

Keith Tolley — Patient Advocate

Caressa Valduezza, NP — Weill Cornell Medicine

Sarah A. Weiss, MD — Rutgers Cancer Institute

Michael K. Wong, MD, PhD, FRCPC — The University of Texas MD Anderson Cancer Center